The Associate Director, Cancer Prevention Research Program, will be responsible for the overall planning, coordination and monitoring of a worldwide Cancer Prevention Program designed to provide prompt evaluation of new leads in cancer prevention. The Cancer Prevention Research Program has a staff of approximately 46 who administer a large intramural and extramural program with a budget of approximately $30 million annually.

This is a Civil Service position in the Senior Executive Service (SES) with an annual salary compensation between ES-1 through ES-4 (currently $68,700 to $76,400 per annum). In addition, physicians may be eligible for a Physician's Comparability Allowance up to $20,000 per year. (Applicants alternatively may be eligible for appointment in the Commissioned Corps of the U.S. Public Health Service.) The individual selected, if not presently in SES, must serve a one-year probationary period.

Applicants must meet the minimum educational requirements for Medical Officer, GS-602. Applicants must further meet established mandatory professional/technical and managerial/executive requirements. Applicants will be further evaluated on the degree to which they possess/additional desirable qualifications in the areas of professional/technical qualifications, managerial/executive qualifications, scientific reputation/peer recognition, training and education, and honors and awards. A copy of the requirements may be obtained by contacting Ms. Dolores Guido in the Personnel Management Branch, NCI, at (301) 496-8182.

Applications for Federal Employment (SF-171), are to be sent to the above individual at:

The National Cancer Institute Personnel Management Branch 9000 Rockville Pike Building 31, Room 3A19 Bethesda, Maryland 20892

A current curriculum vitae and bibliography must accompany all applications for entrance into the SES. Resumes are not acceptable applications for entrance into the SES. Public Health Service Commissioned Officers wishing to enter the SES must follow the above procedures. Officers interested in performing the duties of the position within the Commissioned Corps may submit a resume to the above address.

Applications must be received by February 2, 1990.

SELECTION FOR THIS POSITION WILL BE BASED SOLELY ON MERIT, WITH NO DISCRIMINATION FOR NON-MERIT REASONS SUCH AS RACE, COLOR, RELIGION, SEX, NATIONAL ORIGIN, POLITICS, MARITAL STATUS, PHYSICAL HANDICAP, AGE, OR MEMBERSHIP OR NON-MEMBERSHIP IN AN EMPLOYEE ORGANIZATION.

NIH IS AN EQUAL OPPORTUNITY EMPLOYER

Over the last 40 years, research programs supported by the American Cancer Society have made increasing progress in the treatment, detection and prevention of cancer.

In 1986 alone, the Society funded over 700 projects conducted by the most distinguished scientists and research institutions in the country.

Which is why, this year, hundreds of thousands of people will be successfully treated for the disease.

We are winning.
But we need you to help keep it that way.

AMERICAN CANCER SOCIETY
Help us keep winning.
Cancer Research
VOLUME 50 • NUMBER 1
CONTENTS Arranged by Subject Category

Editorial
1 Message from the New Editor-in-Chief. Carlo M. Croce.

Review

BASIC SCIENCES

Biochemistry and Biophysics

Carcinogenesis
113 Morphology and Anatomic Localization of Renal Micro-neoplasms and Proximal Tubule Dysplasias Induced by Four Different Estrogens in the Hamster. Stanley Goldfarb and Thomas D. Pugh.

Endocrinology

Immunology


*159 Enhancement of Monoclonal Antibody Uptake in Human Colon Tumor Xenografts following Irradiation. H. Kalofonos, G. Rowlinson, and A. A. Epenotos.

Molecular Biology and Genetics
*44 Allelic Losses of Chromosomes 9, 11, and 17 in Human Bladder Cancer. Yvonne C. Tsai, Peter W. Nichols, Alan L. Hiti, Zippora Williams, Donald G. Skinner, and Peter A. Jones.


Preclinical Pharmacology and Experimental Therapeutics
15 Dose-dependent Effects of Hydralazine on Microcirculatory Function and Hyperthermic Response of Murine F5ns Tumors. Joachim Kalmus, Paul Okuniew, and Peter Vaupel.


*138 Selective Delivery of Boron by the Melanin Precursor Analogue p-Boronophenylalanine to Tumors Other Than Melanoma. Jeffrey A. Codesser, John D. Glass, Ralph G. Fairchild, Peggy L. Micca, Irwin Ford, and Darrel D. Joel.

Tumor Biology
*10 Establishment of Continuous Cultures of T-Cell Acute Lymphoblastic Leukemia Cells at Diagnosis. Ruth Gjerset, Alice Yu, and Martin Haas.

*20 Differentiation of U-937 Histiocytic Lymphoma Cells towards Mature Neutrophilic Granulocytes by Dibutyryl Cyclic Adenosine-3',5'-monophosphate. Debra L. Laskin, Andrew J. Beavis, Andrea A. Sirak, Sean M. O'Connell, and Jeffrey D. Laskin.

* Indicates studies using human-derived material.


142 Experimental Induction of Neoplasia in the Accessory Sex Organs of Male Lobund-Wistar Rats. Dennis M. Hoover, Kevin L. Best, Brian K. McKenney, Roy N. Tamura, and Blake L. Neubauer.

CLINICAL AND EPIDEMIOLOGICAL INVESTIGATIONS

Clinical


197 Relationship between Dihydropyrimidine Dehydrogenase Activity and Plasma 5-Fluorouracil Levels with Evidence for Circadian Variation of Enzyme Activity and Plasma Drug Levels in Cancer Patients Receiving 5-Fluorouracil by Protracted Continuous Infusion. Barry E. Harris, Ruiling Song, Seng-jaw Soong, and Robert B. Diasio.


Epidemiological


211 Announcements

Eighty-first Annual Meeting of the AACR
AACR Special Conferences in Cancer Research
Future Annual Meetings of the AACR
Collected Perspectives in Cancer Research
Recent Deaths
Calendar of Events

212 Errata


213 Instructions for Authors

219 Author Index

NOTE: AACR forms available in the back of this issue—
• 1990 Employment Register Forms and Instructions
• Application for Associate Membership
• Advance Registration Form for the 81st Annual Meeting